广泛期小细胞肺癌免疫治疗疗效预测  

Prediction of Efficacy of Immunotherapy for Extensive Stage Small Cell Lung Cancer

作　　者：李斯琴高娃 呼群[2] 

机构地区：[1]内蒙古医科大学,第一临床医学院,内蒙古 呼和浩特 [2]内蒙古医科大学附属医院肿瘤内科,内蒙古 呼和浩特

出　　处：《临床医学进展》2023年第5期8519-8525,共7页Advances in Clinical Medicine

摘　　要：小细胞肺癌(small cell lung cancer, SCLC)是异质性、侵袭性较强的神经内分泌肿瘤。由于SCLC恶性程度极高,极早发生远处转移,且确诊时大多已进入广泛期小细胞肺癌(extensive stage small cell lung cancer, ES-SCLC)。虽然ES-SCLC对化疗极度敏感,但其进展速度极快,故预后极差。因此,为ES-SCLC患者提供新的治疗方案尤为重要。近年来,免疫治疗已经在SCLC治疗方面取得了一些进展。免疫治疗不仅价格昂贵而且有些患者会出现较为严重的不良反应,因此寻找有效生物标记物用来评估患者免疫治疗是否获益从而减轻患者的病痛折磨及经济负担的关键。本研究针对ES-SCLC免疫治疗疗效及预测生物标志物进行综述。Small cell lung cancer (SCLC) is a heterogeneous and aggressive neuroendocrine tumor. Due to the extremely high degree of malignancy of SCLC, distant metastasis occurs very early, and most pa-tients have entered extensive stage small cell lung cancer (ES-SCLC) when diagnosed. Although ES-SCLC is extremely sensitive to chemotherapy, it progresses rapidly and has a poor prognosis. Therefore, it is particularly important to provide new treatment options for patients with ES-SCLC. In recent years, immunotherapy has made some progress in the treatment of SCLC. Immunotherapy is not only expensive but also causes serious adverse reactions in some patients. Therefore, the search for effective biomarkers is the key to evaluating whether patients benefit from immuno-therapy. This study reviews the efficacy and predictive biomarkers of ES-SCLC immunotherapy.

关 键 词：小细胞肺癌 免疫治疗 治疗疗效 生物标志物 

分 类 号：R73[医药卫生—肿瘤]